射血分数减低的慢性心力衰竭的管理。

IF 2.4 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

Journal of the American Board of Family Medicine Pub Date : 2024-05-01 DOI:10.3122/jabfm.2023.230436R1

Brandon Williamson, Carl Tong

{"title":"射血分数减低的慢性心力衰竭的管理。","authors":"Brandon Williamson, Carl Tong","doi":"10.3122/jabfm.2023.230436R1","DOIUrl":null,"url":null,"abstract":"Heart failure with reduced ejection fraction (HFrEF) is a commonly seen clinical entity in the family physician's practice. This clinical review focuses on the pharmacologic management of chronic HFrEF. Special attention is paid to the classification of heart failure and the newest recommendations from the American Heart Association concerning the use of guideline-directed medical therapy. β blockers, ACE inhibitors, ARBs, mineralocorticoid receptor antagonists are discussed in detail. The new emphasis on sacubitril-valsartan and SGLT2i's as therapies for HFrEF are reviewed, followed by a brief discussion of more advanced therapies and comorbidity management.","PeriodicalId":50018,"journal":{"name":"Journal of the American Board of Family Medicine","volume":"37 3","pages":"364-371"},"PeriodicalIF":2.4000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Management of Chronic Heart Failure with Reduced Ejection Fraction.\",\"authors\":\"Brandon Williamson, Carl Tong\",\"doi\":\"10.3122/jabfm.2023.230436R1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Heart failure with reduced ejection fraction (HFrEF) is a commonly seen clinical entity in the family physician's practice. This clinical review focuses on the pharmacologic management of chronic HFrEF. Special attention is paid to the classification of heart failure and the newest recommendations from the American Heart Association concerning the use of guideline-directed medical therapy. β blockers, ACE inhibitors, ARBs, mineralocorticoid receptor antagonists are discussed in detail. The new emphasis on sacubitril-valsartan and SGLT2i's as therapies for HFrEF are reviewed, followed by a brief discussion of more advanced therapies and comorbidity management.\",\"PeriodicalId\":50018,\"journal\":{\"name\":\"Journal of the American Board of Family Medicine\",\"volume\":\"37 3\",\"pages\":\"364-371\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the American Board of Family Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3122/jabfm.2023.230436R1\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Board of Family Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3122/jabfm.2023.230436R1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

射血分数降低型心力衰竭（HFrEF）是家庭医生临床实践中常见的一种疾病。本临床综述侧重于慢性 HFrEF 的药物治疗。其中特别关注心力衰竭的分类以及美国心脏协会关于使用指导性药物治疗的最新建议。详细讨论了β受体阻滞剂、血管紧张素转换酶抑制剂、血管紧张素转换酶抑制剂、矿皮质激素受体拮抗剂。此外，还回顾了作为 HFrEF 治疗方法的 sacubitril-valsartan 和 SGLT2i 的新重点，随后简要讨论了更先进的疗法和合并症管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Management of Chronic Heart Failure with Reduced Ejection Fraction.

Heart failure with reduced ejection fraction (HFrEF) is a commonly seen clinical entity in the family physician's practice. This clinical review focuses on the pharmacologic management of chronic HFrEF. Special attention is paid to the classification of heart failure and the newest recommendations from the American Heart Association concerning the use of guideline-directed medical therapy. β blockers, ACE inhibitors, ARBs, mineralocorticoid receptor antagonists are discussed in detail. The new emphasis on sacubitril-valsartan and SGLT2i's as therapies for HFrEF are reviewed, followed by a brief discussion of more advanced therapies and comorbidity management.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of the American Board of Family Medicine 医学-医学：内科

CiteScore

4.90

自引率

6.90%

发文量

168

审稿时长

4-8 weeks

期刊介绍： Published since 1988, the Journal of the American Board of Family Medicine ( JABFM ) is the official peer-reviewed journal of the American Board of Family Medicine (ABFM). Believing that the public and scientific communities are best served by open access to information, JABFM makes its articles available free of charge and without registration at www.jabfm.org. JABFM is indexed by Medline, Index Medicus, and other services.